Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has selected two molecules, ML-133 and LT-253, as lead candidates for further development as novel anticancer drugs, based on the results of preclinical studies.
Subscribe to our email newsletter
ML-133 and LT-253 are part of the ML-series, which is a group of novel low molecular weight compounds that shows significant anti-proliferative activity against many human cancer cell lines.
In the in vitro anticancer screening program of the US National Cancer Institute (NCI), which includes 60 human cancer cell lines representing nine cancer types, ML-133 exhibited potent activity against colon carcinoma, leukemia, non-small cell lung cancer, and prostate cancer cell lines.
Lorus and collaborators at the University of Toronto are currently in the process of developing formulations of ML-133 and LT-253 to characterize pharmacokinetic properties. The goal of these studies is to advance drug candidates into clinical trials as quickly as possible.